Michael Bush, MD
Endocrinology · Beverly Hills, CANPI 1144208950
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $322,988 of the $379,592 with a category attached, or 85.1%. Lilly USA, LLC accounts for 72.5% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $156,810 and has fallen 83.0% since, to $26,685 in 2025. Among endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 705 payments — averaging $538.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$275K
- Boehringer Ingelheim$28K
- AstraZeneca$27K
- Novo Nordisk$26K
- Johnson & Johnson$10K
- Sanofi-aventis U.S. LLC$9K
- plus $4K from 22 others
What the payments were for
- Consulting fees$18,5905%
- Speaking & faculty fees$322,98885%
- Travel & lodging$27,1887%
- Food & beverage$10,5223%
- Education$3040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 445 | $275,294 |
| Boehringer Ingelheim | 47 | $28,118 |
| AstraZeneca | 43 | $27,280 |
| Novo Nordisk | 36 | $26,180 |
| Johnson & Johnson(2 entities) | 12 | $9,563 |
| Sanofi-aventis U.S. LLC | 18 | $8,714 |
| GRT US Holding, Inc. | 3 | $2,132 |
| AbbVie | 19 | $465 |
| Amgen(2 entities) | 17 | $381 |
| Novartis | 13 | $279 |
| Abbott | 11 | $221 |
| Dexcom, Inc. | 2 | $160 |
| Merck | 8 | $153 |
| GSK | 6 | $131 |
| Pfizer | 4 | $91 |
| Bayer | 4 | $79 |
| Recordati_rare_diseases_inc. | 2 | $57 |
| Mannkind Corporation | 3 | $48 |
| IBSA Pharma Inc. | 2 | $47 |
| Philips North America LLC | 1 | $28 |
| Vistapharm, Inc. | 2 | $27 |
| Genentech USA, Inc. | 1 | $24 |
| Heartflow, Inc. | 1 | $23 |
| Medline Industries LP | 1 | $21 |
| Optos, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Valeritas, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$379,592 in reported general payments places this provider in the 95th percentile of 58 endocrinology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 218 | $236,813 |
| OzempicSemaglutide | 204 | $236,009 |
| TrulicityDulaglutide | 155 | $218,784 |
| MounjaroTirzepatide | 68 | $71,256 |
| RybelsusSemaglutide | 36 | $50,864 |
| JanumetSitagliptin Phos/Metformin Hcl | 49 | $47,999 |
| FarxigaDapagliflozin Propanediol | 29 | $38,892 |
| SynjardyEmpagliflozin/Metformin Hcl | 40 | $38,332 |
| ProliaDenosumab | 21 | $35,768 |
| InvokanaCanagliflozin | 26 | $33,072 |
| Tresiba Flextouch U-100Insulin Degludec | 63 | $30,311 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $21,989 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 35 | $21,479 |
| Victoza 3-PakLiraglutide | 18 | $19,989 |
| EliquisApixaban | 20 | $19,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $275,294 | $290,040223 claims |
| Novo NordiskOzempic, Rybelsus | $26,180 | $286,873240 claims |
| Boehringer IngelheimJardiance, Synjardy, Jentadueto | $28,118 | $285,720274 claims |
| MerckJanumet, Januvia, Janumet Xr | $153 | $68,61578 claims |
| AstraZenecaFarxiga | $27,280 | $38,89229 claims |
| AmgenProlia | $381 | $35,76821 claims |
| Johnson & JohnsonInvokana | $9,563 | $33,07226 claims |
| PfizerEliquis, Premarin | $91 | $22,42933 claims |
| AbbVieSynthroid | $465 | $11,718163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 endocrinology providers in California.
Other endocrinology in Beverly Hills
- Paul AzerBeverly Hills$25K
- Minh MachBurbank$559K
- Joseph HawkinsFresno$477K
- Shawna WeislerBurbank$45K
- Ashiq PatelLancaster$32K
- Michael TranAnaheim$16K
- Samuel MayedaOrange$11K
- Daniel KaplanSan Leandro$8K
- Amy van BuiMission Viejo$8K
- Sandeep ChaudharyLaguna Hills$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.